ClinicalTrials.gg
CompletedNCT03547570Updated Apr 30, 2021

Resistance Training for Patients With Hypermobility Spectrum Disorders and Shoulder Symptoms: a Feasibility Study

An interventional study of Progressive heavy shoulder resistance training in Hypermobility Syndrome Shoulder and Shoulder Pain Chronic, sponsored by University of Southern Denmark. Completed at 3 sites in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-04-30.

Sponsored by University of Southern Denmark · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Hypermobility Spectrum Disorders (HSD) is a recent diagnosis that covers joint hypermobility with one or more secondary symptomatic musculoskeletal manifestations. Current clinical management of this population with shoulder symptoms is a non-standardized combination of physiotherapy modalities including exercise prescription. There is evidence suggesting that progressive heavy resistance training increases muscle strength and tendon stiffness, which may be valuable for treatment of this population.

The aim of this study is to evaluate the feasibility of progressive heavy shoulder resistance training (PHSRT) for adults with HSD and shoulder symptoms.

Read the detailed description

Hypermobility Spectrum Disorders (HSD) is a recent diagnosis that covers joint hypermobility with one or more secondary symptomatic musculoskeletal manifestations. Current clinical management of this population with shoulder symptoms is a non-standardized combination of physiotherapy modalities including exercise prescription. There is evidence suggesting that progressive heavy resistance training increases muscle strength and tendon stiffness, which may be valuable for treatment of this population.

The aim of this study is to evaluate the feasibility of progressive heavy shoulder resistance training (PHSRT) for adults with HSD and shoulder symptoms before safely performing a definitive RCT-study in a large cohort. The objectives are to address whether PHSRT is feasible regarding i) patient recruitment and retention, ii) adherence to exercise protocol and its progression levels, iii) completion of objective outcome measures, and iv) registering potential flare up in shoulder symptoms.

Study progression criteria are based on a traffic light system of green (go), amber (amend) and red (stop). Results of these progression criteria will be evaluated by the investigator group, who will recommend amendments that need to be made before proceeding with the definitive RCT.

02

Conditions studied

  • Hypermobility Syndrome Shoulder
  • Shoulder Pain Chronic

Browse trials for

Keywords

  • Joint instability
  • Hypermobility
  • Shoulder
  • Strength training
03

In context

Joint Instability

149 studies on the registry are indexed under Joint Instability; 23 are open to participants now.

This study's enrollment of 12 is below the median of 42 across 82 interventional studies indexed under Joint Instability.

Browse Joint Instability studies →

Lead sponsor

University of Southern Denmark is the lead sponsor of 335 studies on the registry; 45 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women aged 18 - 65
  • Generalized HSD (G-HSD) defined with Beighton score cut-off ≥ 5 for women up to the age of 50 years and ≥ 4 for those above 50 years and all men [21, 22] or historical HSD (H-HSD) if the Beighton score was 1 point below the age and sex-specific cut-off AND the five-part questionnaire (5PQ) was positive (= at least two positive items). In patients with acquired joint limitations (past surgery, wheelchair, amputations) affecting the Beighton score calculation, the assessment of GJH only included a positive 5 part-questionnaire.
  • Present with one or more secondary symptomatic musculoskeletal manifestations, defined as either musculoskeletal pain in minimum one shoulder for at least three months or recurrent joint dislocations or joint instability without a reported history of trauma defined as: a) minimum three atraumatic dislocations in same shoulder or minimum two atraumatic dislocations in two different joints (minimum one in the shoulder) occurring at different times, or b) medical confirmation of joint instability in minimum two joints (minimum one in the shoulder) not related to trauma.

Exclusion criteria

Exclusion Criteria:

  • Clinically suspected referred pain from the cervical spine
  • Systemic rheumatic diseases (e.g. Marfans, Stickler's or Loeys Dietz syndromes)
  • Neurological diseases
  • Pregnancy or childbirth within the latest year
  • Shoulder surgery within the past year
  • Inability to speak and understand Danish.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Heavy shoulder resistance training

    Progressive heavy shoulder resistance training performed twice a week at the physiotherapy clinic under supervision, while once weekly training at home will be recommended.

    Other: Progressive heavy shoulder resistance training

Interventions

  • OtherProgressive heavy shoulder resistance training

    The training programme includes five exercises identified in literature to target scapular and rotator cuff muscles.

06

What researchers measure

Primary outcomes

  1. Patient recruitment

    Green: Inclusion rate of one patient per general practitioner or physiotherapist every month (approximately n=6-8/month). Amber: If the recruitment rate falls behind, screening logs and reasons for exclusion will be explored after the first month in order to adjust eligibility criteria (n\<6 after first month) Red: No recruitment after two months

    Time frame: 4 months

  2. Completion of the outcome measures

    Green: 120 minutes for completing all objective outcome measures and at least 67% of patients answering that it was an acceptable duration Amber: Between 121-150 minutes or between 50-66% of patients answering that it was an acceptable duration Red: \>150 minutes or \<50% of patients answering that it was an acceptable duration

    Time frame: Baseline measures

  3. Patient retention

    Green: 10 or more patients show up at 16-weeks follow up Amber: 6-9 patients show up at 16-weeks follow up Red: Less than 6 patients show up at 16-weeks follow up

    Time frame: 4 months

  4. Adherence to training intervention

    Green: At least 75% of patients adhering to at least 75% of training sessions Amber: 50-75% of patients adhering to 50-75% of training sessions Red: \<50% of patients adhering to \<50% of training sessions

    Time frame: 4 months

  5. Adverse events

    Green: No or minor adverse events with no patients discontinuing the trial Amber: Minor or serious adverse events leading to 2 or less patients discontinuing the trial Red: Serious adverse events leading to \>2 patients discontinuing the trial

    Time frame: 4 months

Secondary outcomes

  1. WOSI

    Western Ontario Stability Index questionnaire is a tool designed for self-assessment of shoulder function for patients with instability problems. This questionnaire has 21 questions, each scored on a scale from 0 to 100, with 0 being the best score (no limitations related to the shoulder) and 100 representing the worst score. Overall, the questionnaire is scored as a percentage of the maximum score of 2100 points. There are subscale components reporting on: physical symptoms (questions 1 through 10; maximum score of 1000); sports/recreation/work (questions 11 through 14; maximum score 400); lifestyle (questions 15 through 18; maximum score 400); and emotion (questions 19-21; maximum score 300). Subscale scores are added to determine the total score out of a possible 2100 points, with 2100, or 100%, representing the worst possible score.

    Time frame: 4 months

  2. Pain level

    Assessment of shoulder pain will be measured by the Numerical Rating scale of pain (NRS) with numbers from 0 - 10 ("no pain" to "worst pain imaginable"). The pain level will be measured at baseline as the intensity of pain right now, and at 16 weeks follow-up, and in addition, the worst, least and average pain level for the latest week will be measured one time weekly.

    Time frame: 4 months

  3. Checklist Individual Strength (CIS)

    Assessment of fatigue by the Checklist Individual Strength (CIS), subscale fatigue will be performed at baseline and at 16-week follow up to report the change in level of fatigue. CIS Subscale fatigue consists of 8 items each scored on a 7-point Likert scale (scores ranging from 8 to 56) with high scores indicating high levels of fatigue

    Time frame: 4 months

  4. COOP/WONCA

    To assess the change in functional health status from baseline to 16 weeks follow-up the COOP/WONCA questionnaire will be used. The questionnaire is a generic health status questionnaire for General Practice patients. The questionnaire consists of six single-item measures; physical fitness, feelings (mental well-being), daily activities, social activities, besides change in health and overall health. The categories chosen are scored from one (good functional status) to five (poor functional status)

    Time frame: 4 months

  5. Tampa Scale of Kinesiophobia (TSK-11)

    Tampa scale of Kinesiophobia is used to measure impression of change in fear of movement from baseline to 16 weeks follow-up. It consists of an 11-item scale where each question is scored on a 4 point Likert scale, with 1 indicating, "strongly disagree" and 4 indicating, "strongly agree". The total scores range from 11-44, with higher scores representing increased fear of movement.

    Time frame: 4 months

  6. Global Perceived Effect (GPE)

    To measure the patients self-rated impression of recovery at follow-up the GPE will be used. GPE measures self-rated impression of recovery since baseline assessment on a 7-point scale (1= worst ever; 2= much worse; 3= a little worse; 4= not changed; 5= a little improved; 6= much improved; and 7= best ever)

    Time frame: 4 months

  7. EQ-5D-5L Health status questionnaire

    The EQ-5D-5L measures change in health related quality of life. It comprises five dimensions (mobility, Self-care, usual activities, pain/discomfort and anxiety/depression). Each dimension is rated using a five-level ordinal scale from no problems to extreme problems. It results in a preference based index that range from states worse than death (\<0), to 1 (full health), anchoring dead at 0. A score of one indicates that the participants perceived their health at the best possible state and a score below null that the participants perceived their health worse than death. In addition, the EQ-5D includes an EQ-VAS where own health "today" is rated on a scale from 0 (worst imaginable health) to 100 (best imaginable health).

    Time frame: 4 months

  8. IPAQ short version

    Physical Activity Questionnaire. To measure the weekly physical activity level the short version of the IPAQ will be used. The IPAQ collects information on time spent on physical activity (PA) at moderate and vigorous intensity and walking in 4 domains: work, transportation, housework/gardening, and leisure time. Questions are supplied with examples of common activities. In all domains, participants are asked to indicate the amount of time spent on PA in the past 7 days in relation to frequency (days) and duration (hours or minutes) of the activity.

    Time frame: 4 months

  9. Isometric shoulder strength

    Maximum isometric voluntary contraction (MVC) in shoulder scaption, internal rotation and external rotation using a hand-held dynamometer.

    Time frame: 4 months

  10. Active and passive shoulder range of motion

    Internal rotation and external rotation with shoulder in 90 degrees of abduction is measured using a HALO digital goniometer.

    Time frame: 4 months

  11. Shoulder proprioception

    Shoulder proprioception is measured in shoulder flexion angles using af HALO digital goniometer.

    Time frame: 4 months

07

Study locations

3 sites
  • GP´s and physiotherapists
    Middelfart, Egion of Southern Denmark, Denmark
  • GP´s and physiotherapists
    Esbjerg, Region Syddanmark, Denmark
  • GP´s and physiotherapists
    Odense, Region Syddanmark, Denmark
08

References and documents

Publications

  • Liaghat B, Skou ST, Jorgensen U, Sondergaard J, Sogaard K, Juul-Kristensen B. Heavy shoulder strengthening exercise in people with hypermobility spectrum disorder (HSD) and long-lasting shoulder symptoms: a feasibility study. Pilot Feasibility Stud. 2020 Jul 10;6:97. doi: 10.1186/s40814-020-00632-y. eCollection 2020. PubMed 32670599 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 30, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03547570
Collaborators
Esbjerg Municipality, Region of Southern Denmark, The Danish Rheumatism Association
Responsible party
Behnam Liaghat (Principal Investigator, University of Southern Denmark) — Principal investigator
First posted
Jun 6, 2018
Start date
May 4, 2018
Primary completion
Nov 6, 2018
Completion
Nov 6, 2018
Last update
Apr 30, 2021

Study contacts

Behnam Liaghat, MSc
principal investigator · University of Southern Denmark
Birgit Juul-Kristensen, PhD
study director · University of Southern Denmark
Søren T Skou, PhD
study chair · University of Southern Denmark, Næstved-Slagelse-Ringsted Hospitals
Karen Søgaard, PhD
study chair · University of Southern Denmark
Jens Søndergaard, MD, PhD
study chair · University of Southern Denmark
Uffe Jørgensen, MD
study chair · Odense University Hospital, University of Southern Denmark

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion